Tudor Investment Corp ET AL purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 32,545 shares of the biopharmaceutical company's stock, valued at approximately $822,000.
A number of other hedge funds also recently modified their holdings of CLDX. Barclays PLC raised its position in Celldex Therapeutics by 140.7% during the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock valued at $4,431,000 after purchasing an additional 76,207 shares in the last quarter. Mirador Capital Partners LP increased its stake in shares of Celldex Therapeutics by 2.9% in the 4th quarter. Mirador Capital Partners LP now owns 119,492 shares of the biopharmaceutical company's stock valued at $3,020,000 after purchasing an additional 3,345 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Celldex Therapeutics by 24.4% during the 4th quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock worth $639,000 after buying an additional 4,967 shares in the last quarter. KBC Group NV lifted its position in shares of Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after buying an additional 1,647 shares during the last quarter. Finally, Sovran Advisors LLC bought a new stake in shares of Celldex Therapeutics during the 4th quarter worth $2,867,000.
Celldex Therapeutics Price Performance
Shares of Celldex Therapeutics stock traded down $0.58 during trading on Tuesday, hitting $19.60. The company's stock had a trading volume of 162,600 shares, compared to its average volume of 887,480. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of -7.63 and a beta of 1.39. Celldex Therapeutics, Inc. has a 52 week low of $14.40 and a 52 week high of $47.00. The stock has a 50-day moving average price of $18.97 and a two-hundred day moving average price of $22.75.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The company had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, equities analysts predict that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several research analysts have commented on the company. UBS Group lowered their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Friday. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. The Goldman Sachs Group decreased their target price on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research note on Friday. Finally, Canaccord Genuity Group initiated coverage on Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 price target for the company. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Celldex Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $53.90.
Read Our Latest Stock Report on CLDX
Celldex Therapeutics Company Profile
(
Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Recommended Stories
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
